NovaBay reports it plans to price public sale of stock with warrants

Deal sells common shares with five-year warrants through Roth Capital

By Devika Patel

Knoxville, Tenn., Oct. 22 – NovaBay Pharmaceuticals, Inc. will price a public offering of common shares and five-year warrants, according to a prospectus supplement filed Thursday with the Securities and Exchange Commission.

Roth Capital Partners is the bookrunner.

Proceeds will be used for working capital and general corporate purposes, including research and development, clinical trials and selling, general and administrative expenses.

NovaBay Pharmaceuticals is a clinical-stage biopharmaceutical company based in Emeryville, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.